AMDL statement includes going concern

AMDL (Tustin, California), an international biopharma company with operations in China through its subsidiary, Jade Pharmaceutical Inc., reported that its consolidated financial statements for the year ended December 31, 2006, which were included in its annual report on form 10-KSB filed with the SEC contained a going concern qualification from its independent registered public accounting firm KMJ Corbin & Company.

This announcement is in compliance with the AMEX company guide rule 610(b) requiring a public announcement of the receipt of an audit opinion that contains a going concern qualification. This announcement does not reflect any change or amendment to the consolidated financial statements as filed.

DoveBid to expand online equipment auction

DoveBid (Los Angeles), a provider of capital asset auction and valuation services, reported that it has expanded its auction exchange program to include an online durable medical equipment exchange (DMEX).

The first DMEX online auction will be conducted May 2-3, 2007, from 12:00 am PDT until 5:00 pm PDT at http://www.dovebid.com and will feature clinical trial assets from pharmaceutical company Pfizer. Assets include state-of-the-art laboratory equipment, X-ray systems, an ultrasound system, LDX analyzers, digital instruments, defibrillators, IVUS imaging systems and vital signs monitors.

Sellers can consign assets into the DoveBid DMEX by contacting the company or visiting DoveBid's web site.

PTS Cholesterol test strip certified

Polymer Technology Systems (PTS; Indianapolis) reports that it has obtained certification by the cholesterol reference method laboratory network (CRMLN) for its cholesterol test strip for use by point-of-care by physicians, pharmacies, and other healthcare professionals, as well as by consumers at home.

CRMLN certifies manufacturers of clinical diagnostic products that measure total cholesterol using reference methods or designated comparison methods that are rigorously standardized to the CDC reference methods. The FDA has recognized the value of the CRMLN's certification program and encourages manufacturers to certify their products through the CRMLN.

"We are very proud to make this announcement," said PTS CEO Robert Huffstodt, "as it again validates the accuracy of our cholesterol test. After widespread acceptance by professionals around the world, we recently made a version of our CardioChek system available to consumers at retailers across the country for the first time. Those who have already purchased a system and those thinking about purchasing a system can rest assured that our cholesterol test meets the requirements of this difficult certification process."

NIH Pain consortium to look at research

Leading pain researchers will discuss advances in understanding and managing pain at a one-day symposium sponsored by the NIH Pain Consortium (Bethesda, Maryland). Presentations will cover neuropathic pain, visceral pain, inflammatory pain and treatment-induced pain. A poster session will feature work by junior investigators. Researchers, health care providers, reporters and the public are invited to attend this free meeting. The meeting will be held today from 8:30-5:00 in the Masur Auditorium on the NIH Campus.

Featured speakers include a dozen NIH-supported researchers, the directors of the NIH neurology and nursing institutes, NIH pain research program directors and a representative of the American Pain Society. An agenda, directions and registration information are available online.

No Comments